2剂与3剂乙型肝炎疫苗与急性心肌梗死的关联
该研究在Kaiser Permanente Southern California(KPSC)15个医疗中心开展前瞻性非劣效性队列研究,纳入2018年8月7日至2019年10月31日期间在家庭医学或内科接受至少1剂乙型肝炎疫苗的69 625名非透析成人,比较HepB-CpG疫苗与HepB-alum疫苗受种者接种后13个月内1型急性心肌梗死的发生率。结果显示,HepB-CpG组确认52例事件(1.67/1000人年),HepB-alum组71例(1.86/1000人年),绝对率差-0.19(95%CI -0.82至0.44),校正HR 0.92(单侧97.5%CI上限1.32,低于非劣效界值2),非劣效P<.001。结论认为HepB-CpG疫苗与HepB-alum疫苗相比未达到急性心肌梗死风险增加的统计学标准。
要点
- 在69 625名非透析成人中,HepB-CpG组1型急性心肌梗死发生率为1.67/1000人年,HepB-alum组为1.86/1000人年,绝对率差-0.19(95%CI -0.82至0.44)。
- 校正HR为0.92(单侧97.5%CI上限1.32),低于预设非劣效界值2,非劣效P<.001。
- 研究采用IPTW校正人口学与临床特征后两组特征均衡,潜在事件经诊断代码识别并由心脏病专家裁定。
- 随访时间为指数剂量后13个月,最终随访至2020年11月30日。
适用人群与场景
- 在KPSC家庭医学或内科接受至少1剂乙型肝炎疫苗、未接受透析的成人,2018年8月7日至2019年10月31日期间接种,最终随访至2020年11月30日。
研究设计与关键结果
- 研究类型为前瞻性队列非劣效性研究,在KPSC(整合医疗系统,15个医疗中心,约470万成员)开展,纳入69 625名非透析成人,比较HepB-CpG疫苗与HepB-alum疫苗。
- HepB-CpG组31 183人(中位年龄49岁,IQR 38-56岁;51.2%男性,n=15 965;52.7%西班牙裔,n=16 423),HepB-alum组38 442人(中位年龄49岁,IQR 39-56岁;50.8%男性,n=19 533;47.1%西班牙裔,n=18 125),IPTW后特征均衡。
- 主要终点为指数剂量后13个月内1型急性心肌梗死,HepB-CpG组确认52例(1.67/1000人年),HepB-alum组71例(1.86/1000人年),绝对率差-0.19(95%CI -0.82至0.44)。
- 校正HR 0.92(单侧97.5%CI上限1.32),低于非劣效界值2,非劣效P<.001。
证据类型、等级与局限
- 证据类型:前瞻性队列非劣效性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,与HepB-alum疫苗相比,接种HepB-CpG疫苗未达到急性心肌梗死风险增加的统计学标准。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The 2-dose hepatitis B vaccine with a cytosine phosphoguanine adjuvant (HepB-CpG vaccine; Heplisav-B) generated higher seroprotection in prelicensure trials than did a 3-dose hepatitis B vaccine with an aluminum hydroxide adjuvant (HepB-alum vaccine; Engerix-B). However, in 1 trial, a higher number of acute myocardial infarction (MI) events were observed among those who received the HepB-CpG vaccine than among those who received the HepB-alum vaccine, an outcome requiring further study.
OBJECTIVE: To compare the rate of acute MI between recipients of HepB-CpG vaccine and HepB-alum vaccine.
DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort noninferiority study was conducted at Kaiser Permanente Southern California (KPSC), an integrated health care system with 15 medical centers and approximately 4.7 million members. The study included 69 625 adults not undergoing dialysis who received at least 1 dose of a hepatitis B vaccine in either family medicine or internal medicine departments at KPSC from August 7, 2018, to October 31, 2019 (November 30, 2020, final follow-up).
EXPOSURES: Receipt of HepB-CpG vaccine vs HepB-alum vaccine. The first dose during the study period was the index dose.
MAIN OUTCOMES AND MEASURES: Individuals were followed up for 13 months after the index dose for occurrence of type 1 acute MI. Potential events were identified using diagnosis codes and adjudicated by cardiologists. The adjusted hazard ratio (HR) of acute MI was estimated comparing recipients of HepB-CpG vaccine with recipients of HepB-alum vaccine, with inverse probability of treatment weighting (IPTW) to adjust for demographic and clinical characteristics. The upper limit of the 1-sided 97.5% CI was compared with a noninferiority margin of 2.
RESULTS: Of the 31 183 recipients of HepB-CpG vaccine (median age, 49 years; IQR, 38-56 years), 51.2% (n = 15 965) were men, and 52.7% (n = 16 423) were Hispanic. Of the 38 442 recipients of HepB-alum (median age, 49 years; IQR, 39-56 years), 50.8% (19 533) were men, and 47.1% (n = 18 125) were Hispanic. Characteristics were well-balanced between vaccine groups after IPTW. Fifty-two type 1 acute MI events were confirmed among recipients of HepB-CpG vaccine for a rate of 1.67 per 1000-person-years, and 71 type 1 acute MI events were confirmed among recipients of HepB-alum vaccine for a rate of 1.86 per 1000 person-years (absolute rate difference, -0.19 [95% CI, -0.82 to 0.44]; adjusted HR, 0.92 [1-sided 97.5% CI, ∞ to 1.32], which was below the noninferiority margin; P < .001 for noninferiority).
CONCLUSIONS AND RELEVANCE: In this cohort study, receipt of HepB-CpG vaccine compared with HepB-alum vaccine did not meet the statistical criterion for increased risk of acute myocardial infarction.
参考来源
- Bruxvoort K, Slezak J, Qian L, et al. Association Between 2-Dose vs 3-Dose Hepatitis B Vaccine and Acute Myocardial Infarction. JAMA. 2022. PMID: 35333303. doi:10.1001/jama.2022.2540
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。